Table 2

Activity of rituximab in patients with Burkitt leukemia

Percent survival
MDACC9 Germany19 CALGB20 
Therapy 4 years 3 years 4 years 
Chemotherapy 50 50 52 
Chemotherapy + rituximab 77 79 78 
Percent survival
MDACC9 Germany19 CALGB20 
Therapy 4 years 3 years 4 years 
Chemotherapy 50 50 52 
Chemotherapy + rituximab 77 79 78 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal